PF-04950615 (RN316)

BIOLOGICAL4 trials

Sponsors

Pfizer

Conditions

DyslipidemiaDyslipidemiasHypercholesterolemiaHyperlipidemiasLipid Metabolism DisordersMetabolic Diseases

Phase 1

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

CompletedNCT01243151

PfizerDyslipidemia, Hypercholesterolemia

Start: 2011-02-28End: 2011-10-31Updated: 2019-01-22

A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

CompletedNCT01435382

PfizerDyslipidemias, Hypercholesterolemia, Hyperlipidemias +2

Start: 2011-10-31End: 2012-04-30Updated: 2018-07-23

Phase 2

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

CompletedNCT01342211

PfizerDyslipidemia, Hypercholesterolemia

Start: 2011-07-31End: 2012-06-30Updated: 2017-10-11

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

CompletedNCT01350141

PfizerDyslipidemia, Hypercholesterolemia

Start: 2011-06-30End: 2012-06-30Updated: 2017-11-08

Related Papers

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.

2017-10-149 citations